Significant
advances
have
been
made
in
the
management
of
diabetes
through
development
wearable
biomedical
monitoring
and
drug-delivery
devices.
Technologies
such
as
continuous
glucose
monitors
(CGMs)
insulin
pumps
particularly
transformed
care
over
past
two
decades.
However,
most
current
efforts
largely
focus
on
regulation,
limiting
a
broader
understanding
metabolic
health
interplay
various
biomarkers.
Comprehensive
requires
more
holistic
approach
encompassing
diverse
biomarkers
to
address
full
spectrum
health.
Adequate
response
glycemic
variability
thus
additional
chemical
physical
parameters
that
affect
sensitivity.
Leveraging
recent
microneedle
(MN)
platforms,
systems
received
considerable
attention
for
applications,
ranging
from
multiplexed
transdermal
drug
delivery.
This
review
article
provides
thorough
analysis
use
MNs
enhanced
management,
emphasizing
their
unique
capabilities
simultaneous
multiple
key
beyond
autonomous
delivery
glucagon
based
novel
glucose-responsive
MN
materials
addressing
literature
gaps
regarding
integration
diagnostic
treatment
technologies
onto
single
arrays.
Representative
applications
sensing
devices
are
highlighted,
underscoring
revolutionize
disease
management.
We
conclude
with
forward-looking
vision
next-generation
AI-guided
MN-based
closed-loop
"Sense-Release"
artificial
pancreas
control
improved
patient
outcomes.